Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk amid investor concerns that the Danish drugmaker has lost its first-mover advantage in the lucrative weight-loss ...

Novo Nordisk launches its first GLP-1 product, liraglutide, branded as Victoza in 2009 in Europe and in 2010 in the U.S. In 2013, Novo Nordisk's semaglutide starts global phase 3 trials.